| 1 |
35288472 | Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients. | 2022 Apr 1 |
1 |
| 2 |
32686582 | Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion. | 2021 Apr |
3 |
| 3 |
33530945 | Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series. | 2021 Feb 2 |
2 |
| 4 |
34345437 | A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera® treatment. | 2021 Jul-Sep |
4 |
| 5 |
34512507 | Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Dimethylfumarate. | 2021 |
3 |
| 6 |
34849598 | Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. | 2021 Nov 29 |
1 |
| 7 |
31583427 | Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. | 2020 Jan |
1 |
| 8 |
32440353 | Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis. | 2020 Apr-Jun |
1 |
| 9 |
31066225 | Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment. | 2019 Sep |
1 |
| 10 |
31208265 | A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. | 2019 Oct |
1 |
| 11 |
31417557 | Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis. | 2019 |
1 |
| 12 |
28436295 | Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. | 2018 Apr |
1 |
| 13 |
28258191 | Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients. | 2017 Apr 15 |
2 |
| 14 |
28377940 | Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. | 2017 May |
6 |
| 15 |
29141823 | Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies. | 2017 Nov |
3 |
| 16 |
26767188 | Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. | 2016 Feb |
4 |
| 17 |
25738172 | Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. | 2015 Jun |
1 |